Innate Pharma S.A. (IPH.PA)
EUR 1.98
(-3.37%)
EUR 1.98
(-3.37%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 30.6 Million EUR | -23.77% |
| 2022 | 40.14 Million EUR | 197.33% |
| 2021 | 13.5 Million EUR | -20.31% |
| 2020 | 16.94 Million EUR | 2.12% |
| 2019 | 16.59 Million EUR | 422.61% |
| 2018 | 3.17 Million EUR | -29.77% |
| 2017 | 4.52 Million EUR | 11.27% |
| 2016 | 4.06 Million EUR | 29.73% |
| 2015 | 3.13 Million EUR | -16.55% |
| 2014 | 3.75 Million EUR | -10.77% |
| 2013 | 4.2 Million EUR | 26.42% |
| 2012 | 3.32 Million EUR | 0.0% |
| 2011 | - EUR | -100.0% |
| 2010 | 6.78 Million EUR | -10.17% |
| 2009 | 7.55 Million EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | -100.0% |
| 2006 | 2.72 Million EUR | 562.53% |
| 2005 | 411 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 26.41 Million EUR | -13.71% |
| 2024 Q2 | 26.41 Million EUR | 0.0% |
| 2023 Q3 | 30.95 Million EUR | -12.36% |
| 2023 Q4 | 30.6 Million EUR | -1.13% |
| 2023 FY | 30.6 Million EUR | -23.77% |
| 2023 Q1 | 35.32 Million EUR | -12.02% |
| 2023 Q2 | 35.32 Million EUR | 0.0% |
| 2022 Q2 | 12.52 Million EUR | 0.0% |
| 2022 Q1 | 12.52 Million EUR | -7.26% |
| 2022 FY | 40.14 Million EUR | 197.33% |
| 2022 Q4 | 40.14 Million EUR | 0.0% |
| 2022 Q3 | 40.14 Million EUR | 220.6% |
| 2021 Q4 | 13.5 Million EUR | 0.0% |
| 2021 Q2 | 14.48 Million EUR | 0.0% |
| 2021 Q1 | 14.48 Million EUR | -14.52% |
| 2021 FY | 13.5 Million EUR | -20.31% |
| 2021 Q3 | 13.5 Million EUR | -6.78% |
| 2020 Q1 | 16.78 Million EUR | 1.13% |
| 2020 FY | 16.94 Million EUR | 2.12% |
| 2020 Q4 | 16.94 Million EUR | 0.0% |
| 2020 Q3 | 16.94 Million EUR | 0.98% |
| 2020 Q2 | 16.78 Million EUR | 0.0% |
| 2019 Q2 | 3.23 Million EUR | 0.0% |
| 2019 Q3 | 16.59 Million EUR | 412.6% |
| 2019 Q4 | 16.59 Million EUR | 0.0% |
| 2019 Q1 | 3.23 Million EUR | 1.95% |
| 2019 FY | 16.59 Million EUR | 422.61% |
| 2018 FY | 3.17 Million EUR | -29.77% |
| 2018 Q4 | 3.17 Million EUR | 0.0% |
| 2018 Q3 | 3.17 Million EUR | -18.15% |
| 2018 Q2 | 3.87 Million EUR | 0.0% |
| 2018 Q1 | 3.87 Million EUR | -14.2% |
| 2017 FY | 4.52 Million EUR | 11.27% |
| 2017 Q1 | 3.45 Million EUR | -14.87% |
| 2017 Q2 | 3.45 Million EUR | 0.0% |
| 2017 Q4 | 4.52 Million EUR | 0.0% |
| 2017 Q3 | 4.52 Million EUR | 30.7% |
| 2016 Q3 | 4.06 Million EUR | 25.71% |
| 2016 FY | 4.06 Million EUR | 29.73% |
| 2016 Q4 | 4.06 Million EUR | 0.0% |
| 2016 Q2 | 3.23 Million EUR | 0.0% |
| 2016 Q1 | 3.23 Million EUR | 3.19% |
| 2015 FY | 3.13 Million EUR | -16.55% |
| 2015 Q2 | 3.52 Million EUR | 0.0% |
| 2015 Q3 | 3.13 Million EUR | -11.05% |
| 2015 Q4 | 3.13 Million EUR | 0.0% |
| 2015 Q1 | 3.52 Million EUR | -6.18% |
| 2014 Q3 | 3.75 Million EUR | -5.73% |
| 2014 FY | 3.75 Million EUR | -10.77% |
| 2014 Q4 | 3.75 Million EUR | 0.0% |
| 2014 Q1 | 3.98 Million EUR | -5.35% |
| 2014 Q2 | 3.98 Million EUR | 0.0% |
| 2013 Q3 | 4.2 Million EUR | 43.7% |
| 2013 FY | 4.2 Million EUR | 26.42% |
| 2013 Q1 | 2.92 Million EUR | -12.17% |
| 2013 Q2 | 2.92 Million EUR | 0.17% |
| 2013 Q4 | 4.2 Million EUR | 0.0% |
| 2012 Q3 | 131 Thousand EUR | 0.0% |
| 2012 FY | 3.32 Million EUR | 0.0% |
| 2012 Q4 | 3.32 Million EUR | 2439.69% |
| 2012 Q2 | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 FY | - EUR | -100.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 FY | 6.78 Million EUR | -10.17% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 Q4 | 6.78 Million EUR | 0.0% |
| 2009 Q4 | 7.55 Million EUR | 0.0% |
| 2009 FY | 7.55 Million EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | -100.0% |
| 2006 FY | 2.72 Million EUR | 562.53% |
| 2005 FY | 411 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -2679.927% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 31.523% |
| Adocia SA | 4.54 Million EUR | -574.163% |
| Aelis Farma SA | 2.04 Million EUR | -1394.482% |
| Biophytis S.A. | 3.11 Million EUR | -883.832% |
| Advicenne S.A. | 15.89 Million EUR | -92.545% |
| genOway Société anonyme | 5.51 Million EUR | -454.545% |
| IntegraGen SA | 642.28 Thousand EUR | -4665.367% |
| Medesis Pharma S.A. | 1.2 Million EUR | -2450.583% |
| Neovacs S.A. | 650 Thousand EUR | -4608.769% |
| NFL Biosciences SA | 39.2 Thousand EUR | -77973.107% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -602.558% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -1461.32% |
| Sensorion SA | 1.24 Million EUR | -2366.494% |
| Theranexus Société Anonyme | 2.46 Million EUR | -1143.824% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -685.198% |
| TheraVet SA | 1 Million EUR | -2958.868% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -343.194% |
| argenx SE | 15.35 Million EUR | -99.342% |
| BioSenic S.A. | 15.57 Million EUR | -96.539% |
| Celyad Oncology SA | 902 Thousand EUR | -3293.237% |
| DBV Technologies S.A. | 4.52 Million USD | -576.248% |
| Galapagos NV | 4.94 Million EUR | -519.074% |
| Genfit S.A. | 62.25 Million EUR | 50.834% |
| GeNeuro SA | 6.49 Million EUR | -371.435% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -8797.384% |
| Inventiva S.A. | 25.61 Million EUR | -19.484% |
| MaaT Pharma SA | 5.42 Million EUR | -464.184% |
| MedinCell S.A. | 52.8 Million EUR | 42.032% |
| Nanobiotix S.A. | 41.66 Million EUR | 26.531% |
| Onward Medical N.V. | 16.3 Million EUR | -87.704% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -787.001% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 13.803% |
| Oxurion NV | 117 Thousand EUR | -26059.829% |
| Pharming Group N.V. | 123.65 Million EUR | 75.249% |
| Poxel S.A. | 40.14 Million EUR | 23.755% |
| GenSight Biologics S.A. | 1.04 Million EUR | -2820.515% |
| Transgene SA | 17 Thousand EUR | -179941.176% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 98.937% |
| Valneva SE | 132.76 Million EUR | 76.947% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |